Sana Biotechnology ( NASDAQ: SANA) was upgraded to Market Outperform from Market Perform at Citizens as the research broker ...

Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Sana Biotechnology in a research report issued to clients and investors on Tuesday, March 18th. HC Wainwright analyst E. Bodnar ...

Sana Biotechnology (NASDAQ:SANA – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a ...

Asana stock remains challenged in the face of CEO Dustin Moskovitz’s sudden retirement and a downbeat outlook for the current ...

Sana Biotechnology operates in a highly competitive and rapidly evolving biotechnology sector. With a beta of 1.64 according to InvestingPro, the stock exhibits higher volatility than the broader ...

Reports cash equivalents, and marketable securities as of December 31, were $152.5M compared to $205.2M as of December 31, 2023. The decrease ...

SEATTLE (AP) — SEATTLE (AP) — Sana Biotechnology Inc. (SANA) on Monday reported a loss of $49.1 million in its fourth quarter. The Seattle-based company said it had a loss of 21 cents per share.

On Tuesday, Sana Biotechnology shares received an upgrade from Citizens JMP, shifting the company’s stock rating from Market Perform to Market Outperform. The biotechnology firm, traded under ...

Sana Biotechnology operates in a highly competitive and rapidly evolving biotechnology sector. With a beta of 1.64 according to InvestingPro, the stock exhibits higher volatility than the broader ...

SEATTLE (AP) — SEATTLE (AP) — Sana Biotechnology Inc. (SANA) on Monday reported a loss of $49.1 million in its fourth quarter. The Seattle-based company said it had a loss of 21 cents per share.